STOK · Stoke Therapeutics, Inc.

Revenue fell 96.1% year-over-year to $6.2 million in Q1 2026 from $158.6 million, primarily due to the lack of a large one-time milestone payment recorded in the prior-year period. As a clinical-stage biotechnology company without commercialized products, Stoke Therapeutics' revenue remains episodic and dependent on partnership milestones rather than steady product sales. This normalization reveals the underlying topline vulnerability, shifting reliance to internal funding for R&D amid no disclosed near-term replacements for such inflows.

Operating income swung to a $53.4 million loss from a $111.2 million profit, representing a -148.0% YoY change, as elevated expenses overwhelmed the diminished revenue base. The -857.6% operating margin underscores how R&D and operational costs—tied to advancing the genetic medicines platform—now dominate the income statement. Net income followed suit, posting a $50.0 million loss versus $112.9 million profit (-144.3% YoY), with diluted EPS at -$0.79 compared to $1.90 (-141.6% YoY). These shifts confirm the transition from milestone-driven gains to investment-phase losses characteristic of pre-revenue biotech.

Filings emphasize persistent liquidity risks, with expected losses pressuring working capital. Investors should monitor clinical milestones, as the cost structure demands disciplined execution to sustain operations through development phases.